Research progress on Sirtuins (SIRTs) family modulators.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular pathways and drug mechanisms without primary human data or systematic synthesis.
PubMed 38522239 · doi:10.1016/j.biopha.2024.116481
What was done
This narrative review synthesizes literature on the mammalian sirtuin family (SIRT1 to SIRT7), their molecular structures, and their roles as NAD+-dependent protein deacetylases. The authors detail the classification, history, mechanisms of action for sirtuin agonists and inhibitors, and review potential clinical applications and future research challenges.
What was found
The abstract provides no numerical data or quantitative outcomes. It describes qualitatively that sirtuins regulate cellular aging, metabolism, oxidative stress, and tumor biology, and highlights that pharmacological modulators targeting these enzymes show therapeutic potential in cancer, autoimmune conditions, and cardiovascular disorders.
Why it matters
Targeting sirtuin enzymes remains an active avenue for therapeutic development across aging and metabolic disorders; this review organizes current modulation strategies and biological mechanisms.
Limits
The paper is a non-systematic narrative review providing mechanistic overviews rather than primary human clinical trial data. No search criteria, study counts, quantitative effect sizes, or safety data are provided in the abstract.
Cited by
- supports Sirtuin enzymes require nicotinamide adenine dinucleotide (NAD) to carry out their deacetylation reaction.